Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

Open access

Published version of a preprint

Abstract

The efficacy and potential limitations of molecular residual disease (MRD) detection urgently need to be fully elucidated in a larger population of non-small cell lung cancer (NSCLC). We enrolled 261 patients with stages I to III NSCLC who underwent definitive surgery, and 913 peripheral blood samples were successfully detected by MRD assay. Within the population, only six patients (3.2%) with longitudinal undetectable MRD recurred, resulting in a negative predictive value of 96.8%. Longitudinal undetectable MRD may define the patients who were cured. The peak risk of developing detectable MRD was approximately 18 months after landmark detection. Correspondingly, the positive predictive value of longitudinal detectable MRD was 89.1%, with a median lead time of 3.4 months. However, brain-only recurrence was less commonly detected by MRD (n = 1/5, 20%). Further subgroup analyses revealed that patients with undetectable MRD might not benefit from adjuvant therapy. Together, these results expound the value of MRD in NSCLC. SIGNIFICANCE: This study confirms the prognostic value of MRD detection in patients with NSCLC after definitive surgery, especially in those with longitudinal undetectable MRD, which might represent the potentially cured population regardless of stage and adjuvant therapy. Moreover, the risk of developing detectable MRD decreased stepwise after 18 months since landmark detection. This article is highlighted in the In This Issue feature, p. 1599.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-1486

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Flow diagram of patient inclusion in subanalyses with clinical questions answered by each analysis denoted.
Figure 1. Flow diagram of patient inclusion in subanalyses with clinical questions answered by each analysis denoted.CC BY-NC-ND · PubMed Central
Figure 2. Study schematic and baseline characteristics. A, Study flowchart. Patients with stage I to III NSCLC (tumor diameter ≥2 cm) treated with definitive surgery were enrolled. Peripheral blood samples were collected before surgery and every 3 to 6 months after surgery. B, Heat map plot based on baseline characteristics and preoperative ctDNA tests of each patient. C, Multivariate logistic regression model for preoperative ctDNA detection. Pathologic type (adenocarcinoma) and SUVmax were independently associated with preoperative ctDNA detection. D, Detection rate of preoperative ctDNA in patients with different pathologic types. E, Detection rate of preoperative ctDNA in patients with different groups of SUVmax subgroup. F, Schematic diagram of residual blood sample collection from resected lung lobe. G, Comparison between two peripheral blood samples and residual blood ctDNA analysis of additional 11 patients with stage I NSCLC. AD, adenocarcinoma; Chemo, chemotherapy; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor; TMB, tumor mutation burden.
Figure 2. Study schematic and baseline characteristics. A, Study flowchart. Patients with stage I to III NSCLC (tumor diameter ≥2 cm) treated with definitive surgery were enrolled. Peripheral blood samples were collected before surgery and every 3 to 6 months after surgery. B, Heat map plot based on baseline characteristics and preoperative ctDNA tests of each patient. C, Multivariate logistic regression model for preoperative ctDNA detection. Pathologic type (adenocarcinoma) and SUVmax were independently associated with preoperative ctDNA detection. D, Detection rate of preoperative ctDNA in patients with different pathologic types. E, Detection rate of preoperative ctDNA in patients with different groups of SUVmax subgroup. F, Schematic diagram of residual blood sample collection from resected lung lobe. G, Comparison between two peripheral blood samples and residual blood ctDNA analysis of additional 11 patients with stage I NSCLC. AD, adenocarcinoma; Chemo, chemotherapy; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor; TMB, tumor mutation burden.CC BY-NC-ND · PubMed Central
Figure 3. MRD monitoring after surgery. A, The NPV and PPV of undetectable and detectable MRD at landmark and longitudinal time points, respectively. B, NPV and PPV of undetectable and detectable MRD at longitudinal time points across different stages. C, Kaplan–Meier analysis of DFS stratified by landmark MRD status: detectable (n = 21) versus undetectable (n = 224). D, Kaplan–Meier analysis of DFS stratified by longitudinal MRD status: detectable (n = 46) versus undetectable (n = 190). E, Kaplan–Meier analysis of DFS stratified by longitudinal MRD status across different stages. F, Kaplan–Meier analysis of time to MRD detection and time to imaging recurrence from the end of treatment for all patients. G, Flowchart of occurrence time of MRD or recurrent events in stage II/III patients; the peak timeframe of detectable MRD occurrence was 12 to 18 months after surgery. H, Estimated hazard rate curves for event occurrences in stage II/III patients with landmark-undetectable MRD (n = 85, events were defined as detectable MRD or disease recurrence).
Figure 3. MRD monitoring after surgery. A, The NPV and PPV of undetectable and detectable MRD at landmark and longitudinal time points, respectively. B, NPV and PPV of undetectable and detectable MRD at longitudinal time points across different stages. C, Kaplan–Meier analysis of DFS stratified by landmark MRD status: detectable (n = 21) versus undetectable (n = 224). D, Kaplan–Meier analysis of DFS stratified by longitudinal MRD status: detectable (n = 46) versus undetectable (n = 190). E, Kaplan–Meier analysis of DFS stratified by longitudinal MRD status across different stages. F, Kaplan–Meier analysis of time to MRD detection and time to imaging recurrence from the end of treatment for all patients. G, Flowchart of occurrence time of MRD or recurrent events in stage II/III patients; the peak timeframe of detectable MRD occurrence was 12 to 18 months after surgery. H, Estimated hazard rate curves for event occurrences in stage II/III patients with landmark-undetectable MRD (n = 85, events were defined as detectable MRD or disease recurrence).CC BY-NC-ND · PubMed Central
Figure 4. Sensitivity analysis and treatment history of 47 patients with recurrence. A, Sensitivity analysis of MRD detection at landmark, longitudinal, and surveillance time points. B, Treatment and MRD test history of all 47 patients with recurrence. Chemo, chemotherapy; TKI, tyrosine kinase inhibitor.
Figure 4. Sensitivity analysis and treatment history of 47 patients with recurrence. A, Sensitivity analysis of MRD detection at landmark, longitudinal, and surveillance time points. B, Treatment and MRD test history of all 47 patients with recurrence. Chemo, chemotherapy; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central
Figure 5. MRD predictive value on adjuvant therapy. A, Heat map plot based on baseline characteristics of patients with detectable MRD at preadjuvant and landmark time points (n = 23). B, Kaplan–Meier analysis of DFS stratified by adjuvant therapy for patients with detectable MRD at preadjuvant and landmark time points: with adjuvant therapy (n = 10) versus without (n = 13). C, Kaplan–Meier analysis of DFS stratified by adjuvant therapy for patients with undetectable MRD at preadjuvant and landmark time points: with adjuvant therapy (n = 45) versus without (n = 182). D, Heat map plot based on baseline characteristics of patients with undetectable MRD at preadjuvant and landmark time points after propensity score matching (PSM). E, After PSM, Kaplan–Meier analysis of DFS stratified by adjuvant therapy for patients with undetectable MRD at preadjuvant and landmark time points: with adjuvant therapy (n = 22) versus without (n = 22). F, Dynamic changes of ctDNA frequency before and after adjuvant therapy for patients with detectable MRD (n = 10), and the DFS of these patients. The arrow represents five of them who still maintained disease-free status. AD, adenocarcinoma; Chemo, chemotherapy; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.
Figure 5. MRD predictive value on adjuvant therapy. A, Heat map plot based on baseline characteristics of patients with detectable MRD at preadjuvant and landmark time points (n = 23). B, Kaplan–Meier analysis of DFS stratified by adjuvant therapy for patients with detectable MRD at preadjuvant and landmark time points: with adjuvant therapy (n = 10) versus without (n = 13). C, Kaplan–Meier analysis of DFS stratified by adjuvant therapy for patients with undetectable MRD at preadjuvant and landmark time points: with adjuvant therapy (n = 45) versus without (n = 182). D, Heat map plot based on baseline characteristics of patients with undetectable MRD at preadjuvant and landmark time points after propensity score matching (PSM). E, After PSM, Kaplan–Meier analysis of DFS stratified by adjuvant therapy for patients with undetectable MRD at preadjuvant and landmark time points: with adjuvant therapy (n = 22) versus without (n = 22). F, Dynamic changes of ctDNA frequency before and after adjuvant therapy for patients with detectable MRD (n = 10), and the DFS of these patients. The arrow represents five of them who still maintained disease-free status. AD, adenocarcinoma; Chemo, chemotherapy; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 230

Metadata

Authors
Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., Yin, K., Jiang, B.-Y., Nie, Q., Liao, R.-Q., Dong, S., Guan, Y., Dai, P., Zhang, X.-C., Yang, J.-J., Tu, H.-Y., Xia, X., Yi, X., Zhou, Q., Zhong, W.-Z., Yang, X.-N., & Wu, Y.-L.
Affiliations
  • Guangdong Academy of Medical Sciences (CN)
  • Jinan University (CN)
  • 2Geneplus-Beijing Institute, Beijing, China.
Corresponding author
  • Yang, Xue-Ning
  • Wu, Yi-Long
Venue
Cancer Discovery
Published
2022-05-11
Volume
12
Issue
7
Pages
1690-1701
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4280569356
Cited by
228
References
33
Citations by year
2026: 35 · 2025: 58 · 2024: 61 · 2023: 61 · 2022: 13
FWCI
20.55
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Guangdong Science and Technology Department Translational Medicine in Lung Cancer (2017B030314120)
  • Leading Medical Talents in Guangdong Province (KJ012019426)
  • Guangdong Provincial People's Hospital Young Talent Project (GDPPHYTP201902, KY012021189)
  • China Postdoctoral Science Foundation (2021M701422)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
molecular residual disease, non-small cell lung cancer, localized lung cancer, recurrence prediction, negative predictive value, adjuvant therapy, prognostic factors, postoperative follow-up
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Prognosis, Neoplasm, Residual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-1486
The paper
Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., Yin, K., Jiang, B.-Y., Nie, Q., Liao, R.-Q., Dong, S., Guan, Y., Dai, P., Zhang, X.-C., Yang, J.-J., . . . Wu, Y.-L. (2022). Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-1486

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.